Related Experiment Video

Updated: Apr 5, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.4K

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System

Xiaojing Wang1, Minghua Sun1, Connie New1

  • 1Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.

ACS Medicinal Chemistry Letters
|August 20, 2015
PubMed

Insights

Adding a methyl group to basic amines can eliminate time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes. This simplified approach helps mitigate drug-drug interactions and potential toxicity, leading to safer therapies.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Medicinal Chemistry

Background:

  • Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes can cause drug-drug interactions and toxicity.
  • Reactive metabolites formed during biotransformation inactivate CYP enzymes, complicating TDI assessment.
  • Developing strategies to mitigate TDI is crucial for discovering safer drug therapies.

Purpose of the Study:

  • To present a simplified approach for addressing CYP3A4 TDI liabilities.
  • To investigate the impact of structural modification on TDI activity.
  • To explore the potential of truncated molecules as surrogates for TDI investigation.

Main Methods:

  • Hypothesized metabolic mechanisms guided the strategy.
  • A methyl group was introduced onto the α carbon of a basic amine.
  • TDI activities of modified truncated and full molecules were evaluated.

Main Results:

  • Complete elimination of TDI activity was observed for both truncated and full molecules (7a and 11) after methyl group addition.
  • The structural modification effectively mitigated CYP3A4 TDI.
  • The study demonstrated a successful strategy for reducing TDI liabilities.

Conclusions:

  • A simplified structural modification can effectively eliminate CYP3A4 TDI.
  • Truncated molecules may serve as useful surrogates for assessing TDI, with certain limitations.
  • This approach offers a valuable strategy for developing safer therapeutics with reduced drug-drug interaction risks.
Keywords:
CYP3APim kinasesTDImetabolic mechanism

More Related Videos

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

10.6K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K

Related Concept Videos

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
97
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
91
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
378
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
58
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
199
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
117